Eli Lilly Raises Dividend as LLY Stock Benefits From GLP-1 Drug Demand and Obesity Treatment Expansion
Eli Lilly and Company raised its quarterly dividend in 2025 as revenue from GLP-1 receptor agonist drugs Mounjaro and Zepbound continued to exceed Wall Street forecasts. The pharmaceutical giant now pays shareholders $0.87 per share
